Chardan Analysts Initiates Coverage On Akari Therapeutics With A Sell Rating

By: via Benzinga
Although there are catalysts for Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) in 2H16, the inferior dosing schedule for coversin and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.